Retatrutide: a triple incretin receptor agonist for obesity management.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Retatrutide: a triple incretin receptor agonist for obesity management.
- Published In:
- Expert opinion on investigational drugs, 32(11), 1003-1008 (2023)
- Authors:
- Ray, Avik
- Database ID:
- RPEP-07308
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07308APA
Ray, Avik. (2023). Retatrutide: a triple incretin receptor agonist for obesity management.. Expert opinion on investigational drugs, 32(11), 1003-1008. https://doi.org/10.1080/13543784.2023.2276754
MLA
Ray, Avik. "Retatrutide: a triple incretin receptor agonist for obesity management.." Expert opinion on investigational drugs, 2023. https://doi.org/10.1080/13543784.2023.2276754
RethinkPeptides
RethinkPeptides Research Database. "Retatrutide: a triple incretin receptor agonist for obesity ..." RPEP-07308. Retrieved from https://rethinkpeptides.com/research/ray-2023-retatrutide-a-triple-incretin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.